Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression |
| |
| Institution: | 1. Department of Psychiatry, University of Rostock, Rostock, Germany;2. DZNE, German Center for Neurodegenerative Diseases, Rostock, Germany;3. Department of Nuclear Medicine, Charité, University Medicine of Berlin, Campus Mitte, Berlin, Germany;4. Department of Psychiatry, Psychosomatic Medicine & Psychotherapy, Goethe University, Frankfurt, Germany;5. Department of Neurology, Neurodegeneration Research Laboratory (NRL), University of Rostock, Rostock, Germany;1. Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan;2. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan;3. Department of Cell Therapy, Institute of Biomedical Research and Innovation, Kobe, Japan;4. Department of General Clinical Research Center, Kobe City Medical Center General Hospital, Kobe, Japan;5. Department of Clinical Pathology, Kobe City Medical Center General Hospital, Kobe, Japan;1. Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan;2. Institute of Bioinformatics and Biosignal Transduction, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan;3. Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan;1. Wearable Computing Lab., ETH Zurich, Switzerland;2. ACTLab, University of Passau, Germany;1. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan;2. Department of Hematology, Toyota Kosei Hospital, Toyota, Japan;3. Department of Haematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan;4. Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan;5. Division of Virology, National Cancer Center Research Institute, Tokyo, Japan;6. Department of Clinical Laboratories, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan;1. Department of Medicine, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, United States;2. Department of Radiology, University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, United States;1. Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA;2. Department of Biomedical and Diagnostic Sciences, University of Tennessee College of Veterinary Medicine, Knoxville, TN, USA |
| |
| Abstract: | There are important recent developments in Alzheimer's disease (AD) translational research, especially with respect to the imaging of amyloid pathology in vivo using MRI and PET technologies. Here we exploit the most widely used transgenic mouse models of amyloid pathology in order to relate the imaging findings to our knowledge about the histopathological phenotype of these models. The development of new diagnostic criteria of AD necessitates the use of biological markers to diagnose AD even in the absence of overt dementia or early symptomatic mild cognitive impairment. The validity of the diagnosis will depend on the availability of an in vivo marker to reflect underlying neurobiological changes of AD. Transgenic models with essential features of AD pathology and mechanisms provide a test setting for the development and evaluation of new biological imaging markers.Among the best established imaging markers of amyloid pathology in transgenic animals are high-field MRI of brain atrophy, proton spectroscopy of neurochemical changes, high-field MRI of amyloid plaque load, and in vivo plaque imaging using radio-labelled ligands with PET. We discuss the implications of the findings as well as the methodological limitations and the specific requirements of these technologies. We furthermore outline future directions of transgene-imaging research. Transgene imaging is an emerging area of translational research that implies strong multi- and interdisciplinary collaborations. It will become ever more valuable with the introduction of new diagnostic standards and novel treatment approaches which will require valid and reliable biological markers to improve the diagnosis and early treatment of AD patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
